GeneMedi’s AAV2.7m8 variant Rep-Cap plasmid (iner ear&retina-validated serotype AAV-RC plasmid), also named AAV2.7m8 variant-RC plasmid, is part of AAV2.7m8 variant packaging system. AAV2.7m8 variant Rep-Cap plamid supplies the AAV2 Rep(replication) proteins and the AAV2.7m8 variant capsid protein.
You can produce AAV2.7m8 variant paticle in 293T cell line in high titer using GeneMedi’s AAV2.7m8 variant Rep-Cap plasmid with GeneMedi’s AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV2.7m8 vector has been validated in inner ear. AAV2.7m8 infects both inner hair cells (IHCs) and outer hair cells (OHCs) with high efficiency. In addition, AAV2.7m8 infects inner pillar cells and inner phalangeal cells with high efficiency, with potential applications in tissue-specific gene therapy.AAV2-7m8 also shows the potential tropism in retina in vivo and retinal cell in vitro.
AAV2 capsid variant (AAV2.7m8) tissue tropism and gene transduction (serotype-specific AAV infection)
The tissue tropism of AAV2.7m8 vector has been validated in inner ear. AAV2.7m8 infects both inner hair cells (IHCs) and outer hair cells (OHCs) with high efficiency. In addition, AAV2.7m8 infects inner pillar cells and inner phalangeal cells with high efficiency, with potential applications in tissue-specific gene therapy.
Virus and titer: AAV2 variant (AAV2.7m8) vector system, 1×1012 vg/ml
Animal: mouse, C57, 2 months
Infection site: retina
Gene delivery method: subretinal cavity injection, 3μl
Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy